Other studies have linked increased Cpt1a, Pdk4, and Fgf21 with resolution of NASH in human liver biopsies (39), and we did not detect changes in these targets on the initial transcriptomics study. The gene discussed is CPT1A; the disease is metabolic dysfunction-associated steatohepatitis.